Skip to content

menu

Proskauer Rose LLP logo
HomeAboutOur TeamContactSubscribeCurrent Page: All Topics
Search
Close

The Patent Playbook

Key Insights on Trends and Legal Developments in Patent Law

Topics

Antitrust

10x Genomics and Harvard Overcome Patent and Antitrust Hurdles After Settling with Vizgen Inc. View More…

Artificial Intelligence

Impact of the Leadership in Critical Technologies Act on U.S. Artificial Intelligence, Semiconductors and Quantum ComputingThe Role of Generative Artificial Intelligence in Patent Litigation: A New Frontier for Inventorship, Infringement and Validity View More…

Biopharmaceuticals

Federal Circuit Clarifies Reach of “Artificial” Act of Patent InfringementDuty of Candor Continues Before the PTAB or Does it? View More…

Biosimilars

Federal Circuit Clarifies Reach of “Artificial” Act of Patent InfringementThe Supreme Court Kept the Door Open to Genus Claims View More…

Biotechnology

The Supreme Court Kept the Door Open to Genus ClaimsUpdate on Artificial Intelligence: USPTO Urges Federal Circuit to Affirm Decision That AI Cannot Qualify as an “Inventor” View More…

Commercial Litigation

The Broad Impact of Edwards v. Meril on the Safe Harbor ProvisionPTAB Has Authority to Issue Decisions After Statutory Deadline View More…

Diagnostics

In the Orphan Drug Approval Race, Winner Takes All? Ramifications of Catalyst Pharms. v. BecerraSynthetic Data Gets Real View More…

Federal Circuit

Federal Circuit Vacates $300 Million Verdict Against Apple, Orders Third Trial in LTE Patent DisputeEyes Open to the Past: Federal Circuit Holds Prosecution History Is Claim Construction Evidence View More…

Generics

Federal Circuit Clarifies Reach of “Artificial” Act of Patent Infringement“Negative” Patent Claim Limitations—May They be Adequately Described by Omission? View More…

Intellectual Property

Impact of the Leadership in Critical Technologies Act on U.S. Artificial Intelligence, Semiconductors and Quantum ComputingInteresting Recent § 101 Cases – Structural Components Are Not Enough View More…

Inter Partes Review

Discretionary Denials in Action: iRhythm Technologies Inc. v. Welch Allyn Inc.A New Dawn for Patent Owners? Breaking Down the PERA and PREVAIL Acts of 2025 View More…

IP Due Diligence

The Crucial Role of Patent Due Diligence in Mergers & Acquisitions: Spotting Patent Litigation Risks Before Closing a Deal View More…

IP Protection

A New Dawn for Patent Owners? Breaking Down the PERA and PREVAIL Acts of 2025 View More…

Life Sciences

Litigating Patents in the ITC: When and Why Companies Take the Section 337 RouteTo Be Or Not To Be: Self-Revocation of Seminal European Patents Creates New Uncertainty In CRISPR IP Space View More…

Medical Devices

U.S. Medical Device Manufacturers Should Take Note of New European Medical Device RegulationsPrior Art Showing An Invention To Be “At Least Possible” Found Sufficient To Invalidate Surgical Device Patent View More…

Patent Infringement

Interesting Recent § 101 Cases – Structural Components Are Not EnoughEcoFactor v. Google: The Federal Circuit Clarifies Damages Expert Admissibility View More…

Patent Law

Federal Circuit Vacates $300 Million Verdict Against Apple, Orders Third Trial in LTE Patent DisputeEyes Open to the Past: Federal Circuit Holds Prosecution History Is Claim Construction Evidence View More…

Patent Litigation

Federal Circuit Vacates $300 Million Verdict Against Apple, Orders Third Trial in LTE Patent DisputeEyes Open to the Past: Federal Circuit Holds Prosecution History Is Claim Construction Evidence View More…

Patents

A New Dawn for Patent Owners? Breaking Down the PERA and PREVAIL Acts of 2025Beyond the Deal: How are Expiring Patents Fueling M&A in the Life Sciences Industry? View More…

Privacy & Cybersecurity

U.S. Medical Device Manufacturers Should Take Note of New European Medical Device RegulationsSynthetic Data Gets Real View More…

PTAB

Discretionary Denials in Action: iRhythm Technologies Inc. v. Welch Allyn Inc.A New Dawn for Patent Owners? Breaking Down the PERA and PREVAIL Acts of 2025 View More…

Regulatory

A New Dawn for Patent Owners? Breaking Down the PERA and PREVAIL Acts of 2025Litigating Patents in the ITC: When and Why Companies Take the Section 337 Route View More…

Technology

Federal Circuit Vacates $300 Million Verdict Against Apple, Orders Third Trial in LTE Patent DisputeAI, Algorithms and Abstract Ideas: Federal Circuit Reinforces Limits in Recentive v. Fox View More…

Therapeutics

Alleged Theft of Drug Pricing Trade Secrets Could Cost Both Victim and ThiefBridgeBio Transaction Reflects Healthy Market for FDA Priority Review Vouchers View More…

Uncategorized

Patent Litigation and the Rise of Quantum Computing: What to Watch for in the Next Decade View More…
The Proskauer Blog Network
View All Proskauer Blogs

The Patent Playbook

Proskauer Rose LLP logo
Boca Raton|Boston|Chicago|Hong Kong|London|Los Angeles|New Orleans|New York|Paris|São Paulo|Washington, DC
RSS LinkedIn Facebook Twitter Instagram
DisclaimerPrivacy Policy

About Proskauer Rose LLP

We are 800+ lawyers serving clients from offices located in the leading financial and business centers in the Americas, Europe and Asia. The world’s leading organizations, companies and corporations choose us to be their representatives in their most critical situations. Moreover, they consider Proskauer a strategic partner to drive their business forward. We work with asset managers, private equity and venture capital firms, Fortune 500 companies, major sports leagues, entertainment industry legends and other industry-redefining companies.

Visit Proskauer.com

Topics

Archives

Copyright ©2025, Proskauer Rose LLP. All Rights Reserved.
Law blog design & platform by LexBlog LexBlog Logo

Proskauer and our platform provider LexBlog each use cookies to personalize content and ads, to provide social media features and to analyze traffic. Each of us also share information about your use of our site with our social media, advertising and analytics partners. If you are happy for us to store these cookies on your device please click ‘Accept Cookies.' For more information, please see here and here.

OK